News

At Porterhouse, we are proud to support World Amyloidosis Day.  Our article shines a light on this rare condition to help drive greater understanding, improve…

Mohamad Mohty, Head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Sorbonne University, shared a post on X:“Join us for this…

AbstractTransthyretin (TTR) amyloidosis manifests in two distinct forms: hereditary (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt). Despite being one of…

For many living with ATTR-CM amyloidosis, recent advances have brought hope. In just seven years we have gone from no approved treatments to having a number of…

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or…

Variant transthyretin (ATTRv) amyloidosis is a rare, inherited disorder caused by mutations in the TTR gene, leading to amyloid fibril deposition. The Balearic…

AbstractThe accumulation of amyloid fibrils has been identified in tissues outside the brain, yet little is understood about the formation of extracerebral…

July 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a…

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and…

AbstractBackgroundThe diagnosis of cardiac amyloidosis can be achieved noninvasively for transthyretin amyloid cardiomyopathy through nuclear scintigraphy with bone…